Physician profile
Robert M Zuckerman
NPI 1043281496
$27,670.33
in general payments reported to CMS, 2019-2025
41 companies · $3,750 in 2025
The $3,750 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,671 · 2020: $2,548 · 2021: $2,800 · 2022: $3,006 · 2023: $2,862 · 2024: $4,033 · 2025: $3,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,644.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,409.97 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $5,573.49 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $3,834.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,891.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,519.79 | 2019-2025 | Dupixent |
| Optinose US, INC. | $1,502.79 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $734.92 | 2021-2025 | Orladeyo |
| Csl Behring | $653.22 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Grifols USA, LLC | $652.11 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $623.16 | 2020-2024 | Takhzyro, Hyqvia |
| Amgen INC. | $549.33 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $540.02 | 2019-2025 | |
| Genentech USA, INC. | $487.58 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $418.12 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.19 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.